FTG Bio

FTG Bio is a preclinical-stage biotechnology company developing a transformative platform for non-genotoxic conditioning in hematopoietic stem cell (HSC) transplantation. The company's proprietary "First-to-Graft" technology utilizes mRNA-loaded lipid nanoparticles (LNPs) to achieve transient and selective depletion of host stem cells, bypassing the severe side effects associated with traditional chemotherapy and radiation. By enabling safer engraftment of donor or gene-edited cells, FTG Bio aims to expand the clinical utility of HSC-based therapies for patients with sickle cell disease, beta-thalassemia, and various primary immunodeficiencies. As a spin-out from the University of Pennsylvania, the company leverages cutting-edge research in LNP delivery and stem cell biology. FTG Bio is currently advancing its lead programs through the preclinical stage to establish a new standard of care for bone marrow transplantation.